Takeshi Sagara

Company: Taiho Pharmaceuticals Co.,Ltd.

Job title: Managing Director, Clinical Development and Medical Affairs, Discovery & Preclinical Research

Seminars:

Discovery of the First Approved Covalent FGFR Inhibitor, Futibatinib, by Cysteinomix Drug Discovery Approach 3:00 pm

What is the optimal profile of a covalent drug targeting FGFRs, considering target engagement, PKPD, safety and tolerability? How to design covalent binding drugs to capture Cys on highly flexible loop structures What is the desirable platform to continuously deliver covalent binding drug candidates into clinical space?Read more

day: Conference Day Two